Although ibrutinib adds to the cost of treatment, its benefits over the long term justify the cost, investigators found. Adding ibrutinib (Imbruvica) to the R-CHOP regimen (rituximab, cyclophosphamide ...

Dexamethasone pretreatment reduces GI complications in DLBCL patients with GI involvement without compromising efficacy. The study showed no significant differences in response rates or survival ...

R-CHOP plus ibrutinib followed by ibrutinib maintenance induced an ORR of 90% after 4 cycles and 85% at the end of induction. Adding ibrutinib to standard-of-care (SOC) R-CHOP resulted in a 77.7% ...

Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Epcoritamab plus R-CHOP induced high complete metabolic response rates in previously untreated ...

Lenalidomide has significant single-agent activity in relapsed diffuse large B-cell lymphoma (DLBCL). We demonstrated that lenalidomide can be safely combined with R-CHOP (rituximab plus ...

Earlier this year, the FDA approved a new frontline option for patients with diffuse large B-cell lymphoma (DLBCL): the antibody-drug conjugate polatuzumab vedotin (Polivy) in combination with ...

LUGANO, Switzerland — The advent of the Pola-R-CHP (polatuzumab plus R-CHOP) regimen has shaken up the long-held standard of R-CHOP in the treatment of diffuse large B-cell lymphoma (DLBCL) and should ...

The combination of Epkinly and R-mini-CHOP showed a 93% ORR and 86% CR rate in elderly DLBCL patients. At two years, 79% of patients remained in complete response, with a 76% progression-free survival ...

Pivotal studies testing new options in previously untreated double-expressor (MYC/BCL2) diffuse large B-cell lymphoma (DLBCL) yielded differing results, according to findings presented at the recent ...